The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
 
Harry J.M. Groen
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst)
Research Funding - Roche (Inst)
 
Wallace L. Akerley
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences
Research Funding - Bristol-Myers Squibb; Incyte; Loxo
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma Europe (Inst); merrimack (Inst); MSD Oncology; Novartis/Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Novartis; PFIZER; Roche/Genentech
Research Funding - Astellas Pharma (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Novartis; Novartis (Inst); Roche/Genentech (Inst); Sandoz (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; ROCHE; Takeda
 
Eckart Laack
No Relationships to Disclose
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Egbert F. Smit
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck KGaA (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Aaron Scott Mansfield
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Juergen Wolf
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
Daniel Shao-Weng Tan
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Loxo; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer; Roche
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Maeve Waldron-Lynch
No Relationships to Disclose
 
Sylvie Le Mouhaer
Employment - Novartis
 
Ngozi Nwana
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Monica Giovannini
Employment - Novartis
Leadership - AstraZeneca (I); Bluebird Bio (I); Celgene (I); Novartis
Stock and Other Ownership Interests - AstraZeneca (I); Bluebird Bio (I); Celgene (I); Novartis
 
Sergey Orlov
No Relationships to Disclose